CCCC

Over the past six months, C4 Therapeutics' stock (CCCC) has experienced several notable events. The stock was trading at $1.91 at the beginning of 2026 and has since increased by 54.5% to $2.95 as of May 9, 2026. Key events include an expanded partnership with Roche focused on Degrader-Antibody Conjugates (DACs) for cancer treatment, the first patient dosed in a Phase 1b trial of Cemsidomide, the release of Q4 2025 financial results exceeding analysts' expectations, the first patient dosed in the Phase 2 MOMENTUM trial, a clinical trial collaboration with Pfizer Inc., and a stock tumble of -11.3% amidst negative market sentiment.